Study: ENGOT-en31 / RAINFOL-03

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active
BS	Brescia	ASST Spedali Civili	Rossella Franzini	Yes
MB	Monza	Ospedale San Gerardo dei Tintori	Stefania Canova	Yes
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	Yes
PI	Pisa	Ospedale Santa Chiara	Carmelo Bengala	Yes
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna *	Yes

***MaNGO Principal Investigator**